What are your top takeaways from ASCO GU 2022?
My top abstracts and questions that arise from them:
1) ARASENS with darolutamide in high volume de novo mHSPC showing an OS benefit with darolutamide over ADT/docetaxel. Will this pertain only to high volume/risk patients who are chemo-fit and de novo which seemed to comprise the vast majority of ...
The main question after ARASENS trial: Do we give triplet treatment for all newly diagnosed metastatic hormone-sensitive prostate cancer? If not, who will be the ideal patient for triplet treatment vs doublet?
MAGNITUDE and PROpel: Are we ready to gi...
Given positive and new data:
1. QUILT 3.032: Intravesical N803 (IL-15 superagonist) + BCG for BCG-unresponsive NMIBC: CIS group (n=83)-CR=71%, median duration of response (DOR)=24.1 months (mo); Papillary group (n=77)- median DFS 23.6 mo; no therapy related severe adverse events.
Results show promis...
- NRG digital path study as biomarker is important for intermediate risk prostate cancer. Future will be biomarker. This raises the question: Will this be commercially available in the future?
- MRI vs CT for SBRT from UCLA. Here it's more a question of margins and tracking. Will be intere...
Data from ARASENS provides additional supportive data for selected patients presenting with high risk de novo metastatic prostate cancer to receive ADT/docetaxel and an ARI currently abi, but this study will result in broadening of the FDA label of darlutamide.
For DDR...